Placebo and Nocebo Response Mitigation
Empirical Strategies to Mitigate Placebo and Nocebo Effects CenExel sites are committed to enhancing understanding of the causes and implications of the placebo and nocebo...
News at CenExel
CenExel FCR Wins Tampa Bay Times Best of the Best in Clinical Research Award
Tampa, Florida, July 26, 2023 /GlobeNewswire/ — CenExel FCR has been named the 2023 Tampa Bay Times People’s Choice, Best of the Best in Clinical...
Stuart Goldblatt Joins CenExel as CEO
Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our...
Michele Baptista Joins CenExel
Salt Lake City, May 18, 2023 /GlobeNewswire/ — CenExel announces the addition of Michele Baptista as the new Senior Director of Business Development. In this...
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...
CenExel CNS Opens Center in Los Alamitos, California
Los Alamitos, November 29, 2022 /GlobeNewswire/ — CenExel CNS announces the grand opening of the newest clinical research facility in Los Alamitos, California. CenExel CNS...
CenExel Creates Clinical Sciences Business Unit
Salt Lake City, November 15, 2022 /GlobeNewswire/ — CenExel announces a new Clinical Sciences business unit, composed of early phase and translational medicine scientists, plus...
Brandy Isaacks Joins CenExel as Vice President of Project Management & Scientific Affairs
Salt Lake City, October 20, 2022 /GlobeNewswire/ — CenExel announced that Brandy Isaacks has joined their team as Vice President of Project Management and Scientific...
CenExel Acquires Apex Innovative Sciences
Salt Lake City, June 16, 2022 /GlobeNewswire/ — CenExel announces the acquisition of Apex Innovative Sciences, parent company of Collaborative Neuroscience Research (CNS) and Hassman...
